

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/341280213>

Synergistic action of propolis with levodopa in the management of Parkinsonism in *Drosophila melanogaster*

Article in *Journal of Complementary and Integrative Medicine* · May 2020

DOI: 10.1515/jcim-2019-0136

CITATIONS

0

READS

21

16 authors, including:



Ayikobua Emmanuel
Kampala International University (KIU)

14 PUBLICATIONS 12 CITATIONS

[SEE PROFILE](#)



Keneth Iceland Kasozi
Kampala International University (KIU)

27 PUBLICATIONS 65 CITATIONS

[SEE PROFILE](#)



Abass Safiriyu
Indian Institute of Science Education and Research Kolkata

15 PUBLICATIONS 20 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



Ethnopharmacology [View project](#)



Reproductive herd health monitoring of cattle in Central Uganda [View project](#)

Emmanuel Tiyo Ayikobua^{1,2,3,4} / Josephine Kasolo⁵ / Keneth Iceland Kasozi^{3,4,6} / Ejike Daniel Eze³ / Abass Safiriyu^{3,4} / Herbert Izo Ninsiima^{3,7} / Kennedy Kiyimba⁸ / Jackline Namulema⁹ / Edward Jjesero^{3,4} / Fred Ssempijja¹⁰ / Ibrahim Semuyaba³ / Daniel Chans Mwandah⁸ / Kyobe Ronald Kimanje¹¹ / Muhamudu Kalange³ / Alfred Omachonu Okpanachi^{3,4} / Miriam Nansunga^{3,12}

Synergistic action of propolis with levodopa in the management of Parkinsonism in *Drosophila melanogaster*

¹ Department of Physiology, School of Health Sciences, Soroti University, 211 Soroti, Uganda, E-mail: tiyosbase@gmail.com. <https://orcid.org/0000-0002-4743-9622>.

² Department of Physiology, Faculty of Health Sciences, Busitema University Mbale Campus, Box 203 Mbale, Uganda, E-mail: tiyosbase@gmail.com. <https://orcid.org/0000-0002-4743-9622>.

³ Department of Physiology, Faculty of Biomedical Sciences, Kampala International University Western Campus, Box 71, Bushenyi, Uganda, E-mail: tiyosbase@gmail.com, kicelandy@gmail.com, daneze4@gmail.com, alaoabass@gmail.com, hernizz001@yahoo.co.uk, edwardjjesero@gmail.com, ibrahim.semuyaba@kiu.ac.ug, kalangemuhamudu@gmail.com, okpanx@yahoo.com, mnansunga@yahoo.com. <https://orcid.org/0000-0002-4743-9622>, <https://orcid.org/0000-0002-5763-7964>, <https://orcid.org/0000-0002-6016-6091>, <https://orcid.org/0000-0002-5393-9957>, <https://orcid.org/0000-0003-4165-3668>, <https://orcid.org/0000-0002-8647-0956>, <https://orcid.org/0000-0002-3382-0596>, <https://orcid.org/0000-0001-5520-6186>.

⁴ Institute of Biomedical Research Laboratory, Kampala International University, Western Campus, Box 71, Bushenyi, Uganda, E-mail: tiyosbase@gmail.com, kicelandy@gmail.com, alaoabass@gmail.com, edwardjjesero@gmail.com, okpanx@yahoo.com. <https://orcid.org/0000-0002-4743-9622>, <https://orcid.org/0000-0002-5763-7964>, <https://orcid.org/0000-0002-5393-9957>, <https://orcid.org/0000-0002-3382-0596>.

⁵ Department of Physiology, Makerere University College of health Science, Box 7072, Kampala Uganda, E-mail: josephinekasolo57@gmail.com. <https://orcid.org/0000-0001-9551-4423>.

⁶ Department of Animal Production and Management, Faculty of Agriculture and Animal Sciences, Busitema University Arapai Campus, Box 203 Soroti, Uganda, E-mail: kicelandy@gmail.com. <https://orcid.org/0000-0002-5763-7964>.

⁷ Department of Physiology, School of Medicine, Kabale University, Box 317 Kabale, Uganda, E-mail: hernizz001@yahoo.co.uk. <https://orcid.org/0000-0002-6016-6091>.

⁸ Department of Pharmacology, Faculty of Pharmacy, Kampala International University Western Campus, Box 71, Bushenyi, Uganda, E-mail: kiyimbakennedy@gmail.com, danielchanskiu@gmail.com. <https://orcid.org/0000-0001-5791-9016>, <https://orcid.org/0000-0002-1439-5379>.

⁹ Department of Physiology, School of Health Sciences, Uzima University College – CUEA, P.O Box 2502-40100, Kisumu, Kenya, E-mail: jacklineemily@gmail.com. <https://orcid.org/0000-0002-3600-5255>.

¹⁰ Department of Anatomy, Faculty of Biomedical Sciences, Kampala International University Western Campus, Box 71, Bushenyi, Uganda. <https://orcid.org/0000-0003-1849-7185>.

¹¹ Department of Biochemistry, Faculty of Biomedical Sciences, Kampala International University Western Campus, Box 71, Bushenyi, Uganda, E-mail: kimanje.ronald@kiu.ac.ug. <https://orcid.org/0000-0001-6853-9158>.

¹² Department of Physiology, Faculty of Biomedical Sciences, St. Augustine International University, P.O Box 88, Kampala, Uganda, E-mail: mnansunga@yahoo.com. <https://orcid.org/0000-0001-5520-6186>.

Abstract:

Background: The Phosphatase and tensin-induced putative kinase 1 (PINK1^{B9}) mutant for *Drosophila melanogaster* is a key tool that has been used in assessing the pathology of Parkinsonism and its possible remedy. This research was targeted toward determining the effects of ethanolic extract of propolis, with levodopa therapy in the management of Parkinsonism.

Method: The PINK1^{B9} flies were divided into groups and fed with the different treatment doses of ethanoic extract of propolis. The treatment groups were subjected to 21 days of administration of propolis and the levodopa at different doses after which percentage climbing index, antioxidant activity and lifespan studies were done.

Emmanuel Tiyo Ayikobua, Keneth Iceland Kasozi are the corresponding authors.

© 2020 Walter de Gruyter GmbH, Berlin/Boston.

This content is free.

Results: Propolis alone improved motor activity, antioxidant and lifespan in *Drosophila melanogaster* than in PINK1 flies. Propolis in combination with levodopa significantly ($P < 0.05$) improved physiological parameters at higher than lower concentrations in Parkinsonism *Drosophila melanogaster* demonstrating its importance in managing side effects associated with levodopa.

Conclusion: Propolis is a novel candidate as an alternative and integrative medicinal option to use in the management of Parkinsonism in both animals and humans at higher concentrations.

Keywords: aging, antioxidant activity, catalase, climbing index, *Drosophila melanogaster*, Levodopa induced dyskinesia, lifespan, oxidative stress, Parkinson's disease, Parkinsonism, PINK1^{B9}, propolis

DOI: 10.1515/jcim-2019-0136

Received: May 18, 2019; **Accepted:** October 13, 2019

Introduction

Parkinson's disease (PD) is a common disorder affecting 1% of the elderly above 65 years, characterized by the loss of dopaminergic neurons in substantia nigra [1]. Common symptoms are uncontrolled movements such as akinesia, bradykinesia, resting tremor and rigidity. These symptoms are both in humans [2, 3] and in animal models of PD [4, 5]. PTEN-induced putative kinase 1 (PINK1) is responsible for the maintenance of mitochondria structure and function [6–8]. Loss of PINK1 gene in *Drosophila* culminates in a phenotype expressing Parkinsonism, with mitochondrial destruction occurring before muscle degeneration, as well as the destruction of dopaminergic neurons [3]. The *Drosophila melanogaster* PINK1^{B9} mutant model portrays several of these features of PD [3, 9, 10] and has been used to study neuronal dysfunction and neurodegeneration. PINK1^{B9} model provides quite enormous information regarding the pathogenesis of PD and mitochondrial dysfunction [11].

Replacement of dopamine with Levodopa is a cornerstone in treatment for PD [12, 13]. In the basal ganglia, this levodopa is converted to dopamine by aromatic L-amino acid decarboxylase [14]. However, the long-term levodopa therapy (5–10 years from onset of therapy) is often complicated by significantly disabling motor fluctuations and dyskinesia, called levodopa-induced dyskinesia (LID), thus negating its beneficial effects [13]. This is a major disadvantage to levodopa therapy. In the conversion of levodopa to dopamine, the metabolism of dopamine, unlike other neurotransmitters, leads to the yield of dopamine quinones and ROS [15, 16]. Once established, these LIDs are presented with difficulty in treatment and therefore efforts should be made to prevent them [17]. Besides the clinical effects on the patient, LID can affect the quality of life increasing the cost of healthcare and shortening the average lifespan of individuals [18].

Propolis is a resinous material obtained by bees from buds of plant sources near their hives [19]. Propolis is used by bees as a sealant in the hives [20]. Propolis contains over 300 compounds including volatile organic compounds, flavonoid aglycones, phenolic acids, and their esters, phenolic aldehydes, alcohols and ketones, sesquiterpenes, quinones, coumarins, steroids, amino acids [21]. Many natural remedies are employed in the treatment of neurodegenerative disorders [2, 22] but none has been employed as a treatment for LIDs. Propolis extracts were reported to be neuroprotective [23]. Propolis also has broad-spectrum biological and pharmacological properties, such as antioxidant [23], anti-inflammatory [24], antiproliferative [25], anti-cardiovascular diseases, antidiabetic [25] and hepatoprotective activities [26]. Therefore, the aim of this study was to determine if propolis would be a viable candidate for the treatment of LIDs and associated symptoms.

Materials and methods

This study was approved and consented by Institutional Research and Ethics Committee of Kampala International University and the Animal research committee.

Drosophila stocks

Wild type (W¹¹¹⁸) and PTEN-induced putative kinase 1 (PINK1^{B9}) mutant *Drosophila melanogaster* flies were obtained from the Bloomington Stock Center as previously described [27–31]. These flies that were obtained had the red eye balancer, meaning they appeared phenotypically normal but were genetically modified to express parkinsonian symptoms. However, the balancer allowed them to appear normal because the flies that expressed parkinsonian symptoms had greatly impaired functions and this would affect their transportation.

Drosophila culture and crosses

Before the experimentation, the pupae were allowed to emerge from the vials which arrived and flies that expressed the red-eye balancer were selected out using a monocular microscope present in the Institute of Biomedical research Laboratory Kampala International University. These were flies which would express the PINK1^{B9} gene and expressed symptoms of Parkinsonism. These flies were then crossed and larvae were allowed to emerge after which grouping was done.

Drosophila sampling

The number of flies used in each experimental group was seventeen (17) and experiments were conducted in triplicates, thus $17 \times 3 = 51$ flies per group. This sample size was obtained by the use of the power analysis method as done by the G-power software version 3.1 and the flies were divided into groups as shown in Table 1. The total number of flies used in the study was 51×6 groups \times 4 experiments = 1224 flies.

Table 1: Different group allocations used in the experiment, the abbreviations representing them and the rationale of drug and extract administration to their food.

Group label	Drosophila spp.	Treatment	Number of flies in each experiment
WT (Negative control)	w ¹¹¹⁸	No treatment	17×3 repeats = 51
PINK1 ^{B9} (Positive control)	PINK1 ^{B9}	No treatment	$17 \times 3 = 51$
PINK1 ^{B9} /lev (Comparative control)	PINK1 ^{B9}	Levodopa 250 mg/kg	$17 \times 3 = 51$
PINK1 ^{B9} /pro	PINK1 ^{B9}	Propolis 500 mg/mL	$17 \times 3 = 51$
PINK1 ^{B9} /lev/pro ^{250mg/mL}	PINK1 ^{B9}	Propolis 250 mg/mL and levodopa 250 mg/kg of food	$17 \times 3 = 51$
PINK1 ^{B9} /lev/pro ^{500mg/mL}	PINK1 ^{B9}	Propolis 500 mg/mL and levodopa 250 mg/kg of food	$17 \times 3 = 51$

Negative geotaxis

Twenty-one (21) days after experimental exposure, negative geotaxis was conducted using standard protocols [30]. In brief, a vertical distance of 8 cm above the bottom surface was marked by drawing a circle around the entire circumference of the vial and a group of ten flies was transferred into the lower vial carefully preventing the escape of any fly [30]. The number of flies which crossed the 8-cm mark by 10 s after were recorded for 3 consecutive repeats, allowing 1 min rest period between intervals. The number of flies used in this experiment was 51×6 groups = 306 flies.

Antioxidant activity assessment

The molecule 1, 1-diphenyl-2-picrylhydrazyl (DPPH) is characterized as a stable free radical by virtue of the delocalization of the spare electron over the molecule as a whole so that the molecule does not dimerize, as would be the case with most other free radicals. The delocalization of electron also gives rise to the deep violet color, characterized by an absorption band in ethanol solution centered at about 517 nm. When a solution of DPPH is mixed with that of a substrate (AH) that can donate a hydrogen atom, then this gives rise to the reduced form with the loss of this violet color [32]. The antioxidant potential by free radical scavenging of propolis, the change in optical density of DPPH radicals was measured by collecting 0.2 mL of *Drosophila melanogaster* supernatant after feeding on experimental diets and diluting the solution with 2 mL of DPPH solution (0.5 mM). After 30 min in the dark, the absorbance was measured at 517 nm [33]. The number of flies used in this experiment was 51×6 groups = 306 flies and the percentage of the DPPH radical scavenging is calculated using the equation as given below:

$$\% \text{ inhibition of DPPH radical} = \left(\frac{[A_{br} - A_{ar}]}{A_{br}} \right) \times 100; \text{ Where } A_{br} \text{ is the absorbance before reaction and } A_{ar} \text{ is the absorbance after the reaction has taken place.}$$

Catalase activity determination assay

This was determined as previously described [30]. Approximately 200 mL of hydrogen peroxide 95% was obtained then added to Triton ×100 buffer 200 mL. These were mixed slowly and they were added to 200 mL of homogenized fly tissue. The oxygen bubbles produced by enzyme and trapped by the triton X-100 buffer appeared as foam and was measured by height from a standard curve in the form $\text{Absorbance} = 0.056 \text{ catalase activity} + 0.1$, $R^2 = 0.9604$ was generated. The number of flies used in this experiment was $51 \times 6 \text{ groups} = 306$ flies.

Life span studies

The *Drosophila* was kept in groups of eight per vial in two vials one containing male and the other containing female flies as earlier stated. Upon commencement of the lifespan experimentation, virgin flies were allowed to emerge from the pupae and transferred into fresh vials of food. The flies in each vial were counted every 3 days interval and live flies were transferred to new vials while the dead flies were recorded. Flies of the same genealogy were used, to minimize differences arising from genetic backgrounds [30, 31]. The number of flies used in this experiment was $51 \times 6 \text{ groups} = 306$ flies.

Statistical analysis

This was done using Graph Pad Prism Version 6 and information was presented as figures and a Table. ANOVA test was done and Tukey's test was used to determine sources of variation and significant differences ($P < 0.05$) were indicated with different super- scripts i. e. letters a, b, c. The lifespan data were analyzed using Kaplan–Meier survival analysis and Mantel-Cox was performed on the survival curves, with significance being reported when $P < 0.05$.

Results

Combination of propolis and levodopa improved the climbing activity in motor impaired PINK1^{B9}/lev *Drosophila melanogaster*

The study showed that treatment with propolis prevented a decline in motor function significantly and improved the climbing activity in *Drosophila melanogaster*. When compared to the untreated groups, there was a significant increase in the climbing index (Table 2). This improvement was dose-dependent with the group that received 500 mg/mL of propolis (PINK1^{B9}/lev/pro^{500mg/ml}) having a significant improvement in climbing activity compared to the group that received 250 mg/mL (PINK1^{B9}/lev/pro^{250mg/ml}) as shown in Figure 1.

Table 2: Comparisons on climbing activity, catalase and DPPH activity in *Drosophila melanogaster*.

Tukey's multiple comparisons test	Climbing Index	Catalase activity	DPPH activity	Lifespan
Adjusted P values				
WT vs. PINK1 ^{B9}	<0.0001	0.2619	0.2234	
WT vs. PINK1 ^{B9} /lev	<0.0001	0.0015	0.006	
WT vs. PINK1 ^{B9} /prop	<0.0001	<0.0001	0.8636	
WT vs. PINK1 ^{B9} /lev/pro ^{250mg/mL}	<0.0001	0.7027	0.0828	
WT vs. PINK1 ^{B9} /lev/pro ^{500mg/mL}	<0.0001	0.0158	0.9993	Log-rank (Mantel-Cox) test for curve comparisons $X^2(5)=18.52, P=0.0001$
PINK1 ^{B9} vs. PINK1 ^{B9} /lev	0.2362	0.0308	0.1635	
PINK1 ^{B9} vs. PINK1 ^{B9} /prop	>0.9999	<0.0001	0.0368	
PINK1 ^{B9} vs. PINK1 ^{B9} /lev/pro ^{250mg/mL}	>0.9999	0.0257	0.9859	
PINK1 ^{B9} vs. PINK1 ^{B9} /lev/pro ^{500mg/mL}	0.0005	0.0004	0.1343	
PINK1 ^{B9} /lev vs. PINK1 ^{B9} /prop	0.1711	<0.0001	0.001	
PINK1 ^{B9} /lev vs. PINK1 ^{B9} /lev/pro ^{250mg/mL}	0.3195	0.0002	0.6314	

PINK1 ^{B9} /lev vs.	<0.0001	<0.0001	0.0035
PINK1 ^{B9} /lev/pro ^{500mg/mL}			
PINK1 ^{B9} /prop vs.	0.9976	<0.0001	0.0126
PINK1 ^{B9} /lev/pro ^{250mg/mL}			
PINK1 ^{B9} /prop vs.	0.0006	0.0004	0.9647
PINK1 ^{B9} /lev/pro ^{500mg/mL}			
PINK1 ^{B9} /lev/pro ^{250mg/mL} vs.	0.0003	0.1711	0.0475
PINK1 ^{B9} /lev/pro ^{500mg/mL}			




Figure 1: Propolis extract protects PINK1^{B9} *Drosophila melanogaster* flies from motor impairments caused by the 21 days of levodopa therapy.

Key: Experimental groups WT = wildtype (W1118), PINK1 = mutant drosophila with parkinsonism while pro = propolis. Significant differences are represented by different superscripts a, b, c.

Synergistic action of propolis and levodopa on DPPH and hydrogen peroxide scavenging activity in *Drosophila melanogaster*

WT flies (W^{1118*}) showed the highest levels on catalase in comparison to the mutant flies without any treatment (Figure 2(a)). PINK1^{B9} flies under levodopa for 21 days showed significantly lower catalase activity compared to untreated PINK1^{B9} flies demonstrating the oxidative effects of levodopa therapy alone. In addition, a combination of propolis with levodopa was associated with significant ($P < 0.05$) dose-dependent increase in catalase activity and the effective concentration identified was a combination of levodopa and propolis at 500 mg/mL (Table 2). Furthermore, hydrogen peroxide scavenging activity by DPPH was highest in the 500 mg/mL levodopa-propolis combination in comparison to the 250 mg/mL demonstrating that effects are dose dependent. There were no significant differences between propolis administered alone and the effects of the combined therapy at 500 mg/mL as well as the wild type (Figure 2(b) and Table 2) showing that synergistic effects are due to propolis administration and these help restore tissue function as in the normal.




Figure 2: Effects of propolis and levodopa therapy on antioxidant activity in *Drosophila* tissue. (A); depicts the plotted means of catalase activity within the blended tissues of flies from all the 6 groups conducted by a method adapted from Iwase *et al.*, 2013; (B) depicts the plotted means of free radical scavenging activity within the tissues of flies from all the six groups using DPPH.

Experimental groups WT = wildtype (W1118), PINK1 = mutant drosophila with Parkinsonism while pro = propolis. Significant differences are represented by different superscripts a, b, c, d.

Propolis improved the Lifespan in *Drosophila melanogaster*

The study showed that lifespan was highest in the wild-type flies i. e. flies free of Parkinsonism symptoms and PINK1^{B9} flies had significantly shortest lifespan (Figure 3). Propolis alone extended the lifespan in Parkinson flies better than either combination; however 500 mg/mL was more effective in extending lifespan than 250 mg/mL combination of propolis and levodopa.




Figure 3: Lifespan performance in *Drosophila melanogaster* following propolis diet.

Discussion

The study showed that the administration of ethanolic extract of propolis (500 mg/mL) with levodopa (250 mg/kg) not only significantly prevented the motor impairment which has been associated with the long-term use of levodopa but also improved motor function (Figure 1 and Table 2). This was important since Parkinson's disease which is associated with degeneration of dopaminergic receptors is associated with motor dysfunction demonstrating the relevance of the current study [1–5] especially for developing countries where chemotherapeutic options are often limited due to infrastructure challenges, leading to the promotion of alternative medicine. Since propolis contains phenolic hydroxyls [34–36], the observed physiological benefits in *Drosophila melanogaster* are associated with its phytochemical composition. In the study, evidence on the ability to use propolis to manage neurodegeneration following long-term use of levodopa is provided and this was in agreement with previous findings [35, 37]. Since the Parkinsonism phenotype used in this study of PINK1 is associated with mitochondrial function [34, 38], findings in this study offer an insight on the role of propolis in oxidative phosphorylation and hypothesizing the role of phenols in selectively modulating tissue respiration and this was in agreement with previous findings [39–41].

The study also showed that propolis in combination with levodopa effectively increased catalase and reduced concentrations of reactive oxygen species in *Drosophila melanogaster* (Figure 2(a)–(b)). Since levodopa metabolism has been associated with reactive oxygen species [15, 16], findings in the study offer a novel option for use in integrative medicine i. e. use of levodopa and propolis to minimize on the side effects of levodopa therapy. This is important since PD treatment primarily involves replacement of dopamine with levodopa [12, 13], findings in the study revalidate the therapeutical advantages of propolis, thus lower the therapeutical index and would reduce on the incidence of toxicities associated with high levodopa therapies. This would subsequently lead to decreased morbidities and mortalities once findings are translated to humans [18]. In addition, propolis alone is presented as a novel candidate to guide drug discovery due to its superior advantages than the combined therapy at low concentrations (Figure 2 and Table 2). This is important since Parkinson disease is associated with neural damage following excessive accumulation of reactive oxygen species [42–44].

A low survival rate was characterized with all flies having Parkinsonism (Figure 3) due to defective coordination of the skeletomuscular system, leading to decreased ability to look for food, starvation and death (Figure

1). These findings are in agreement with several studies in *Drosophila melanogaster*, demonstrating the importance of an efficient neuromuscular connection to improve on survival [30, 31]. These findings are in agreement with epidemiological studies in humans with Parkinsonism who have been associated with a lower lifespan than healthy individuals [45]. In addition, an extension in lifespan was observed in propolis alone than in either combination with levodopa at either 250 or 500 mg/mL (Figure 3) due to its higher antioxidant activity (Figure 2). These findings are in agreement with previous findings in which flavones from propolis were associated with an increase in lifespan in *Drosophila melanogaster* [46]. A strong antioxidant activity due to activity of DPPH and catalase especially at high concentrations of propolis (Figure 2(b) and Table 2) offers a rationale for its mechanistic potential. Furthermore, using a combined therapy was found to be more effective at higher concentrations showing that the synergistic associated with propolis are dose dependent. This is because propolis is a natural product rich in several organic and inorganic compounds such as phenols and flavonoids [19, 21]. In this study, protective effects associated with propolis therapy in the management of Parkinsonism is in agreement with previous studies which have shown this to be related to the flavonoid content in propolis [46], thus validating it as a candidate for chemotherapeutic development. An increase in antioxidant activity has already been associated with an increase in lifespan in *Drosophila melanogaster* [30] demonstrating the reliability of the current findings.

Conclusion

Propolis in combination with levodopa reduces the toxic effects associated with levodopa side effects in Parkinsonism thus validating it as a candidate for therapeutical development. The use of propolis alone in the management of Parkinsonism was associated with superior performance than in combination with the current conventional therapy. Since experiments in this study were only conducted in triplicates, a follow up study focusing on changes in inflammatory markers, secondary messengers and neurotransmitter activity would offer further insights to guide therapy better since these were not investigated in the current study due to infrastructure limitations.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research Funding: This research was partially funded by Kampala International University.

Employment or leadership: None declared.

Data availability statement: The generated materials containing the raw data are available <https://figshare.com/s/69992acd579396ad5d0c>.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

- [1] Leverenz JB, Quinn JF, Zabetian C, Zhang J, Montine KS, Montine TJ. Cognitive impairment and dementia in patients with Parkinson disease. *Curr Top Med Chem* 2009;9:903–12.
- [2] Ellens DJ, Leventhal DK. Electrophysiology of Basal Ganglia and Cortex in models of Parkinson disease. *J Parkinsons Dis* 2014;3:241–54.
- [3] Le W, Sayana P, Jankovic J. Animal models of Parkinson's disease: a gateway to therapeutics? *Neurotherapeutics* 2014;11:92–110.
- [4] Coune PG, Schneider BL, Aebischer P. Parkinson's disease: gene Therapies. *Cold Spring Harb Perspect Med* 2012;2:a009431–a009431.
- [5] Golden TR, Patel M. Catalytic antioxidants and neurodegeneration. *Antioxid Redox Signal* 2009;11:555–70.
- [6] Fernández-Moriano C, González-Burgos E, Gómez-Serranillos MP. Mitochondria-targeted protective compounds in Parkinson's and Alzheimer's diseases. *Oxid Med Cell Longev* 2015;2015:1–30.
- [7] Riday TT, Dankoski EC, Krouse MC, Fish EW, Walsh PL, Han JE, et al. Pathway-specific dopaminergic deficits in a mouse model of Angelman syndrome. *J Clin Invest* 2012;122:4544–54.
- [8] Inamdar NN, Arulmozhi DK, Tandon A, Bodhankar SL. Parkinson's disease: genetics and beyond. *Curr Neuropharmacol* 2007;5:99–113.
- [9] Camara AK, Lesnfsky EJ, Stowe DF. Potential therapeutic benefits of strategies directed to mitochondria. *Antioxid Redox Signal* 2010;13:279–347.
- [10] Ratliff EP, Mauntz RE, Kotzebue RW, Gonzalez A, Achal M, Barekat A, et al. Aging and autophagic function influences the progressive decline of adult drosophila behaviors. *PLoS one* 2015;10:e0132768. DOI: 10.1371/journal.pone.0132768.

- [11] Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. *Hum Mutation* 2010;31:763–80. DOI: 10.1002/humu.21277.
- [12] Shin JY, Ahn Y-H, Paik M-J, Park HJ, Sohn YH, Lee PH. Elevated homocysteine by levodopa is detrimental to neurogenesis in parkinsonian model. *PLoS ONE* 2012;7:e50496. DOI: 10.1371/journal.pone.0050496.
- [13] Tambasco N, Simoni S, Marsili E, Sacchini E, Murasecco D, Cardaioli G, et al. Clinical aspects and management of levodopa-induced dyskinesia. *Parkinsons Dis* 2012;2012:745947.
- [14] Hogarth P, Horak FB. Effects of Deep Brain Stimulation in Subthalamic. *J Neurosurg* 2014;117:1141–9.
- [15] Barbosa DJ, Capela JP, Oliveira JM, Silva R, Ferreira LM, Siopa F, et al. Pro-oxidant effects of Ecstasy and its metabolites in mouse brain synaptosomes. *Br J Pharmacol* 2012;165:1017–33.
- [16] Béraud D, Hathaway HA, Trecki J, Chasovskikh S, Johnson DA, Johnson JA, et al. Microglial activation and antioxidant responses induced by the Parkinson's disease protein α -synuclein. *J Neuroimmune Pharmacol* 2013 Mar;8:94–117.
- [17] Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. *Postgrad Med J* 2007;83:384–8.
- [18] Guridi J, González-Redondo R, Obeso J a. Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease. *Parkinsons Dis* 2012;2012:1–15.
- [19] Jeong CJ, Choi DK, Ho KS, Heo J. Phenolics of propolis and in vitro protective effects against oxidative stress induced cytotoxicity. *J Agric Life Sci* 2012;46:87–95.
- [20] Libério SA, Pereira AL, Araújo M], Dutra RP, Nascimento FR, Monteiro-Neto V, et al. The potential use of propolis as a cariostatic agent and its actions on mutans group streptococci. *J Ethnopharmacol* 2009;125:1–9.
- [21] Zhang J, Cao X, Ping S, Wang K, Shi J, Zhang C, et al. Comparisons of ethanol extracts of Chinese propolis (Poplar Type) and poplar gums based on the antioxidant activities and molecular mechanism. *Evidence-Based Complement Altern Med* 2015;2015:1–15.
- [22] Seidl SE, Santiago JA, Bilyk H, Potashkin JA. The emerging role of nutrition in Parkinson's disease. *Front Aging Neurosci* 2014;6:1–14.
- [23] Nakajima Y, Shimazawa M, Mishima S, Hara H. Neuroprotective effects of Brazilian Green Propolis and its Main Constituents against Oxygen-glucose Deprivation Stress, with a Gene-expression Analysis. *Physiotherapy Res* 2009;1438:1431–8.
- [24] Goverdhan P, Sravanthi A, Mamatha T. Neuroprotective Effects of Meloxicam and Selegiline in scopolamine-induced cognitive impairment and oxidative stress. *Int J Alzheimers Dis* 2012;2012:1–8.
- [25] Teerasriprecha D, Phuwapraisrisan P, Puthong S, Kimura K, Okuyama M, Mori H, et al. In vitro antiproliferative/cytotoxic activity on cancer cell lines of a cardanol and a cardol enriched from Thai *Apis mellifera* propolis. *BMC Complement Altern Med* 2012;12:27.
- [26] Ibrahim R, Amin A, Mustafa I, Onanuga I, Folarin R, Hepatoprotective BW. Pancreatoprotective properties of the ethanolic extract of Nigerian propolis. *J Intercult Ethnopharmacol* 2015;4:102.
- [27] Cha G-H, Kim S, Park J, Lee E, Kim M, Lee SB, et al. Parkin negatively regulates JNK pathway in the dopaminergic neurons of *Drosophila*. *Proc Natl Acad Sci U S A* 2005;102:10345–50.
- [28] Moroz LL, Kohn AB. Aging studies in *drosophila melanogaster*. *Biol Aging* 2013;1048:323–52.
- [29] Stine RR, Greenspan LJ, Ramachandran KV, Matunis EL. Coordinate regulation of stem cell competition by Slit-Robo and JAK-STAT signaling in the *drosophila* testis. *PLoS Genet* 2014;10:e1004713. DOI: 10.1371/journal.pgen.1004713.
- [30] Kasozi KI, Bukonya A, Eze ED, Kasolo J, Tayebwa DS, Ssempijja F, et al. Low concentrations of *Lactobacillus rhamnosus* GG (Yoba®) are safe in male *Drosophila melanogaster*. *BMC Res Notes* 2019;12:269.
- [31] Kasozi KI, Namubiru S, Kiconco O, Kinyi HW, Ssempijja F, Ezeonwumelu J, et al. Low concentrations of monosodium glutamate (MSG) are safe in male *Drosophila melanogaster*. *BMC Res Notes* 2018;11:670. DOI: 10.1186/s13104-018-3775-x.
- [32] Yang H, Dong Y, Du H, Shi H, Peng Y, Li X. Antioxidant compounds from propolis collected in Anhui, China. *Molecules* 2011;16:3444–55.
- [33] Sforcin J, Fernandes A, Lopes CA, Bankova V, Funari SR. Seasonal effect on Brazilian propolis antibacterial activity. *J Ethnopharmacol* 2000;73:243–9.
- [34] Silva-Carvalho R, Baltazar F, Almeida-Aguiar C. Propolis: a complex natural product with a plethora of biological activities that can be explored for drug development. *Evid Based Complement Alternat Med* 2015;2015:206439.
- [35] Rushdi AI, Adgaba N, Bayaqoob NI, Al-khazim A, Simoneit BR. Characteristics and chemical compositions of propolis from Ethiopia. *Springer Plus* 2014;3:1–9.
- [36] Miguel MC, Nunes S, Dandlen SA, Cavaco AM, Dulce M. Phenols, flavonoids and antioxidant activity of aqueous and methanolic extracts of propolis (*Apis mellifera* L.) from Algarve, South Portugal. *Food Sci* 2014;34:16–23.
- [37] Tolba MF. Caffeic acid phenethyl ester, a promising component of propolis with a plethora of biological activities: A review on its anti-inflammatory, neuroprotective, hepatoprotective, and cardioprotective effects. *Int Union Biochem Mol Biol*. 2013;65:699–709.
- [38] Jeibmann A, Paulus W. *Drosophila melanogaster* as a model organism of brain diseases. *Int J Mol Sci* 2009;10:407–40.
- [39] Poddighe S, De Rose F, Marotta R, Ruffilli R, Fanti M, Secci PP, et al. *Mucuna pruriens* (Velvet bean) rescues motor, olfactory, mitochondrial and synaptic impairment in PINK1B9 *Drosophila melanogaster* genetic model of Parkinson's disease. Nazir A, editor. *PLoS One* 2014;9:e110802.
- [40] Kishore A, Popa T. Cerebellum in levodopa-induced dyskinesias: the unusual suspect in the motor network. *Front Neurol* 2014;5:1–12.
- [41] Zaltieri M, Longhena F, Pizzi M, Missale C, Spano P, Bellucci A. Mitochondrial dysfunction and α -synuclein synaptic pathology in Parkinson's disease: who's on first? *Parkinsons Dis*. 2015;2015:1–10.
- [42] Pedrosa R, Soares-da-silva P. Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. *Br J Pharmacol* 2002;137:1305–13.
- [43] Mazzio EA, Close F, Soliman KF. The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's Disease. *Int J Mol Sci* 2011;12:506–69.
- [44] Ellens DJ, Leventhal DK, Manuscript A, Disease P. Electrophysiology of Basal Ganglia and Cortex in models of Parkinson disease. *J Parkinsons Dis* 2014;3:241–54.
- [45] Ishihara LS, Cheesbrough A, Brayne C, Schrag A. Estimated life expectancy of Parkinson's patients compared with the UK population. *J Neurol Neurosurg Psychiatry* 2007;78:1304–9.

- [46] Zhang C, Ying-jun Y. Effect of propolis flavone on life spans in drosophila and its protective effects against injury by free radicals. J Anhui Tradit Chinese Med Coll 2009;4:154007.